- Home
- OFS vs ATYR Comparison
OFS vs ATYR Comparison
Compare OFS & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OFS | ATYR |
|---|---|---|
| Founded | 2001 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.3M | 49.2M |
| IPO Year | 2010 | 2015 |
Fundamental Metrics
Financial Performance| Metric | OFS | ATYR |
|---|---|---|
| Price | $3.94 | $0.17 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $2.86 |
| AVG Volume (30 Days) | 79.4K | ★ 3.2M |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | ★ 17.35% | N/A |
| EPS Growth | N/A | ★ 6.98 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $190,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.99 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.72 | $0.17 |
| 52 Week High | $7.24 | $1.11 |
Technical Indicators
Market Signals| Indicator | OFS | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 52.05 | 13.94 |
| Support Level | $3.51 | N/A |
| Resistance Level | $3.94 | $0.60 |
| Average True Range (ATR) | 0.16 | 0.02 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 32.78 | 3.32 |
Price Performance
Historical ComparisonAbout OFS OFS Capital Corporation
OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its investment objective is to provide its stockholders with both current income and capital appreciation through debt investments and, to a lesser extent, equity investments.
About ATYR aTyr Pharma Inc.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).